interleukin-8 and thymosin-beta(4)

interleukin-8 has been researched along with thymosin-beta(4)* in 3 studies

Other Studies

3 other study(ies) available for interleukin-8 and thymosin-beta(4)

ArticleYear
Thymosin beta-4 promotes mesenchymal stem cell proliferation via an interleukin-8-dependent mechanism.
    Experimental cell research, 2013, Oct-15, Volume: 319, Issue:17

    Mesenchymal stem cells (MSCs) hold great promise for the field of tissue regeneration. Because only a limited number of MSCs can be obtained from each donor site, it is important to establish standard methods for MSC expansion using growth and trophic factors. Thymosin β4 (Tβ4) is a novel trophic factor that has antimicrobial effects and the potential to promote tissue repair. Tβ4 is a ubiquitous, naturally-occurring peptide in the wound bed. Therefore, the relationship between Tβ4 and MSCs, especially adjacent adipose tissue-derived stem cells (ASCs), merits consideration. Exogenous Tβ4 treatment enhanced the proliferation of human ASCs, resulting in prominent nuclear localization of PCNA immunoreactivity. In addition, exogenous Tβ4 also increased IL-8 secretion and blocking of IL-8 with neutralizing antibodies decreased Tβ4-induced ASC proliferation, suggesting that IL-8 is a critical mediator of Tβ4-enhanced proliferation. Moreover, Tβ4 activated phosphorylation of ERK1/2 and increased the nuclear translocation of NF-κB. These observation provide that Tβ4 promotes the expansion of human ASCs via an IL-8-dependent mechanism that involves the ERK and NF-κB pathways. Therefore, Tβ4 could be used as a tool for MSC expansion in cell therapeutics.

    Topics: Active Transport, Cell Nucleus; Adipose Tissue; Cell Nucleus; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-8; Mesenchymal Stem Cells; Phosphorylation; Proliferating Cell Nuclear Antigen; Thymosin

2013
Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:6

    The mechanisms by which thymosin β 4 (Tβ(4)) regulates the inflammatory response to injury are poorly understood. Previously, we demonstrated that ectopic Tβ(4) treatment inhibits injury-induced proinflammatory cytokine and chemokine production. We have also shown that Tβ(4) suppresses TNF-α-mediated NF-κB activation. Herein, we present novel evidence that Tβ(4) directly targets the NF-κB RelA/p65 subunit. We find that enforced expression of Tβ(4) interferes with TNF-α-mediated NF-κB activation, as well as downstream IL-8 gene transcription. These activities are independent of the G-actin-binding properties of Tβ(4). Tβ(4) blocks RelA/p65 nuclear translocation and targeting to the cognate κB site in the proximal region of the IL-8 gene promoter. Tβ(4) also inhibits the sensitizing effects of its intracellular binding partners, PINCH-1 and ILK, on NF-κB activity after TNF-α stimulation. The identification of a functional regulatory role by Tβ(4) and the focal adhesion proteins PINCH-1 and ILK on NF-κB activity in this study opens a new window for scientific exploration of how Tβ(4) modulates inflammation. In addition, the results of this study serve as a foundation for developing Tβ(4) as a new anti-inflammatory therapy.

    Topics: Actins; Adaptor Proteins, Signal Transducing; Animals; Anti-Inflammatory Agents; Cells, Cultured; Chlorocebus aethiops; COS Cells; DNA-Binding Proteins; Gene Expression Regulation; Humans; Interleukin-8; LIM Domain Proteins; Membrane Proteins; Mutation; NF-kappa B; Protein Binding; Protein Serine-Threonine Kinases; Rats; Thymosin; Transcription Factor RelA; Tumor Necrosis Factor-alpha

2011
Thymosin beta4 is cytoprotective in human gingival fibroblasts.
    European journal of oral sciences, 2008, Volume: 116, Issue:5

    Thymosin beta4 (Tbeta(4)) is a naturally occurring, ubiquitous, non-toxic protein with documented wound-healing, anti-inflammatory, anti-apoptotic, and tissue-repair properties in skin, the ocular surface, and the heart. The ability of Tbeta(4) to demonstrate similar protective properties in cells of the oral cavity was analyzed using an in vitro model of cultured human gingival fibroblasts. Thymosin beta 4 significantly suppressed the secretion of interleukin-8 (IL-8) following stimulation with tumor necrosis factoralpha (TNF-alpha), suggesting that it may suppress the inflammatory response initiated by pro-inflammatory cytokines. By contrast, Tbeta(4) was not effective in protecting fibroblasts from challenge with lipopolysaccharide purified from Porphyromonas gingivalis or Escherichia coli. Thymosin beta 4 was able to protect gingival fibroblasts against the known cytotoxic effects of chlorhexidine digluconate, a mouthrinse containing chlorhexidine digluconate, and carbamide peroxide. Additionally, Tbeta(4) was able to protect gingival fibroblasts from the apoptosis that is induced by stimulation with TNF-alpha or by exposure to chlorhexidine. Because of its multifunctional roles in protecting cells against damage, Tbeta(4) may have significant potential for use as an oral heathcare aid with combined antimicrobial, anti-inflammatory, anti-apoptotic, and cytoprotective properties.

    Topics: Anti-Infective Agents, Local; Apoptosis; Carbamide Peroxide; Cells, Cultured; Chlorhexidine; Cytoprotection; Drug Combinations; Fibroblasts; Gingiva; Humans; Interleukin-8; Lipopolysaccharides; Mouthwashes; Oxidants; Peroxides; Thymosin; Toxicity Tests; Tumor Necrosis Factor-alpha; Urea

2008